Walgreens' Prescription for Growth
We think the pharmacy retailer can further leverage its significant scale.
Founded in 1901, Walgreens Boots Alliance (WBA) is the leading pharmacy retailer, leveraging its scale to provide convenience. The company generates nearly $140 billion in revenue and dispenses over 1 billion prescriptions annually, representing one fourth of the drug market. Its 10,000-plus domestic stores are strategically located in high-traffic areas to generate over $13 million per store, which drives scale and helps the company to negotiate more effectively with suppliers. Scale remains critical in an increasingly competitive market that has witnessed some rationalization of subscale peers. The core business is centered on the pharmacy, which accounts for nearly three fourths of revenue and is the main driver of traffic. Management will need to pull through more volume in the recently acquired Rite Aid locations along with stores abroad as reimbursement stabilizes in Europe.
Management has been focused on leveraging scale to foster strategic partnerships to increase traffic and cross-selling opportunities with a long-term focus on improving coordinated care. Historically, the company’s strategy was based on footprint expansion, but having established a scalable infrastructure, the focus has evolved and the concentration has shifted to improving store utilization and strategically aligning with healthcare partners to address the macro trend of localized community healthcare. WBA has incurred most of the operating and capital investments to successfully complete numerous clinical and consumer packaged goods trials. The successful rollout of these initiatives has not been incorporated into guidance but should help offset continued reimbursement pressures.
Soo Romanoff does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.